At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I, Open-Label, Multicenter, Dose-Escalation Study Of The Tyrosine Kinase Inhibitor Of VEGFR-2, AG013736, In Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating AG-013736 for Advanced Solid Tumors. Completed, enrolled 36 participants across 3 sites.
Detailed Summary
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
Study Details
Timeline
Interventions
Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
Axitinib continuous oral dosing (20 mg twice a day) in the fed state
Axitinib continuous oral dosing (5 mg twice a day) in the fed state
Axitinib continuous oral dosing (15 mg once a day) in the fed state
Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state